From mechanism of disease (MoD) to mechanism of action (MoA)
 

Welcome to the first module of the IBD Training Academy, hosted by Dr Flavio Caprioli and Professor Stefan Schreiber. Module 1 will explore the rationale for different treatment targets in IBD and patient populations who may benefit most from different treatment classes.

Learning objectives

• Summarise the key drivers of pathophysiology in IBD and describe how these are targeted by available and investigational treatments
• Describe the unmet needs associated with current methods of targeting inflammation and how this varies between class and treatment
• Explain how differences in MoA may translate to differences in clinically relevant features (e.g. safety and efficacy, immunogenicity, drug–drug interactions)
• Discuss optimum use of biomarkers in clinical practice and how this may change in the future